儿童心室辅助装置患者的移植后结局:PediMACS-儿童心脏移植研究数据库链接分析
该研究链接PediMACS与儿童心脏移植研究数据库,比较147例移植前使用心室辅助装置(VAD)的儿童与630例无VAD支持的移植患者,发现两组1年移植后生存率、感染豁免率和排斥豁免率均无显著差异,尽管VAD组移植前病情更重。
要点
- VAD组1年移植后生存率96% vs 非VAD组93%,无显著差异(p=0.3)。
- VAD组感染豁免率81% vs 非VAD组79%,无显著差异(p=0.9)。
- VAD组排斥豁免率71% vs 非VAD组74%,无显著差异(p=0.87)。
核心结论
- 儿童VAD患者尽管移植前病情更重,其移植后结局与药物治疗支持的患者相当。
- 移植后生存率、住院时间、感染和排斥不受VAD植入时患者病情严重程度或VAD相关并发症的影响。
- VAD作为移植桥接可减轻儿童病情严重程度。
研究设计与样本
- PediMACS与儿童心脏移植研究数据库链接分析,纳入2012年10月1日至2015年12月31日期间147例移植的VAD患者作为主要研究组,630例无移植前VAD支持的儿童心脏移植研究患者作为对照组。
主要发现
- VAD组植入时INTERMACS profile 1为33例(23%),profile 2为89例(63%),profile 3为14例(10%)。
- VAD组年龄更大、体型更大、先天性心脏病比例更低(p<0.0001)。
- VAD组对正性肌力药和呼吸机支持需求更高,肝肾功能障碍更严重(p<0.0001), device支持后移植时均恢复正常。
- 两组1年移植后生存率96% vs 93%(p=0.3),感染豁免率81% vs 79%(p=0.9),排斥豁免率71% vs 74%(p=0.87),均无显著差异。
关键数值与推荐
- VAD组1年移植后生存率96% vs 非VAD组93%(p=0.3)。
- VAD组感染豁免率81% vs 非VAD组79%(p=0.9)。
- VAD组排斥豁免率71% vs 非VAD组74%(p=0.87)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pediatric ventricular assist device (VAD) support as bridge to transplant has improved waitlist survival, but the effects of pre-implant status and VAD-related events on post-transplant outcomes have not been assessed. This study is a linkage analysis between the PediMACS and Pediatric Heart Transplant Study databases to determine the effects of VAD course on post-transplant outcomes. METHODS: Database linkage between October 1, 2012 and December 31, 2015 identified 147 transplanted VAD patients, the primary study group. The comparison cohort was composed of 630 PHTS patients without pre-transplant VAD support. The primary outcome was post-transplant survival, with secondary outcomes of post-transplant length of stay, freedom from infection and freedom from rejection. RESULTS: At implant, the VAD cohort was INTERMACS Profile 1 in 33 (23%), Profile 2 in 89 (63%) and Profile 3 in 14 (10%) patients. The VAD cohort was older, larger, and less likely to have congenital heart disease (p < 0.0001). However, they had greater requirements for inotrope and ventilator support and increased liver and renal dysfunction (p < 0.0001), both of which normalized at transplant after device support. Importantly, there were no differences in 1-year post-transplant survival (96% vs 93%, p = 0.3), freedom from infection (81% vs 79%, p = 0.9) or freedom from rejection (71% vs 74%, p = 0.87) between cohorts. CONCLUSIONS: Pediatric VAD patients have post-transplant outcomes equal to that of medically supported patients, despite greater pre-implant illness severity. Post-transplant survival, hospital length of stay, infection and rejection were not affected by patient acuity at VAD implantation or VAD-related complications. Therefore, VAD as bridge to transplant mitigates severity of illness in children.
引用
- Sutcliffe DL, Pruitt E, Cantor RS, et al. Post-transplant outcomes in pediatric ventricular assist device patients: A PediMACS-Pediatric Heart Transplant Study linkage analysis. J Heart Lung Transplant. 2017. PMID: 29373179. doi:10.1016/j.healun.2017.12.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。